Coverage of the 2025 Face to Face Drug Plan Management Forum
Running for 20 years, Benefits Canada’s 2025 Face to Face Drug Plan Management Forum is the industry’s most popular drug benefits conference. This year, attendees…
Running for 20 years, Benefits Canada’s 2025 Face to Face Drug Plan Management Forum is the industry’s most popular drug benefits conference. This year, attendees…
As the drug plan landscape evolves, the nuanced tension between cost management and the imperative to support employee health continues, according to a panel of…
As Canada navigates the evolving drug coverage landscape, private drug plans remain a cornerstone of access, innovation and economic growth. Indeed, private drug plans are…
As dermatological treatments move up the ranking of conditions with the highest paid drug claims, they’ve become increasingly significant for private drug plan sponsors, according…
A single drug can be approved for multiple conditions, but each new use requires its own clinical trials and regulatory approval, even if the drug…
Pharmacy benefit managers in Canada have undergone a significant transformation over the years, said Akhil Pandit Pautra, senior manager of clinical services, health claims administration…
“Immunization is one of the best investments money can buy, according to the World Health Organization,” said Johnny Ma, president at Mapol Inc., during a…
Although many medications may seem alike, in the management of chronic conditions, it’s crucial to have access to a broad selection of treatment options to…
For Jocelyn Laidlaw, a former anchor at CTV News, a sudden diagnosis of stage 3A metastatic colorectal cancer revealed not only the emotional toll of…
With only a few weeks left in a year impacted by trade wars, equity concentration risk and the increased appeal of artificial intelligence opportunities, defined…
The current moment is rooted in shifting ideas, characterized by the rise and fall of globalization, said Sean Speer, editor-at-large at the Hub and a…
Fading developed markets bilateral aid and U.S. tariff policy is pushing emerging markets debt as an attractive alternative for growing countries, according to Yvette Babb,…
A quantitative investment process could begin competing with the best fixed income and fundamental traditional credit asset managers in the near future, according to Bernd…
The size of the collateralized loan obligation market is revealing an interest pattern in alternative debt investment opportunities, particularly in Europe and the U.S., according…
CPP Investments’ chief executive officer has described the organization as a supertanker, referring to scale — a portfolio approaching $800 billion — and the inability…
The outlier performance of investments in gold can be traced to risk-off activity from central banks around the world, according to Karlan Patel, vice-president and…
Using journalistic-style investment due diligence can add a differentiated component to a multi-dimensional approach to research, according to Raphael Lewis, head of specialist research at…
By separating a traditional active equity portfolio into two groups, institutional investors can gain resilience and add value at a time when active global equity…
Institutional investors are responsible for setting guardrails and monitoring the use of artificial intelligence tools, rendering standardized guidelines unhelpful at the moment, according to Jacky…
Alongside deglobalization and changing global supply chains, technology is now permeating strategy at a global level, with artificial intelligence moving from a topic of innovation…
Over the last 80 years, the TTC Pension Plan has grown from a contribution of $250,000 and a small team within the Toronto Transit Commission…
While Canada’s financial system was fit for purpose across decades of liberal democratic order, it’s important to look at how the system should be structured…
Canada has the highest rate of multiple sclerosis in the world, with an estimated 90,000 to 100,000 people living with the disease. Every day, 12…
Glioma, the most common malignant brain tumour in young adults under 50 is a devastating disease that often strikes people in their prime working years,…
Health Canada recently approved the first disease-modifying therapy for Alzheimer’s disease, which is a long-awaited milestone that carries significant implications for private drug plans, employers…